Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gilligan's Island Sell Setup | Bearish Swing Setup | -70.04% | |
| Crossed Above 20 DMA | Bullish | -70.04% | |
| Crossed Above 200 DMA | Bullish | -70.04% | |
| Crossed Above 50 DMA | Bullish | -70.04% | |
| MACD Bullish Signal Line Cross | Bullish | -70.04% | |
| New Uptrend | Bullish | -70.04% | |
| Pocket Pivot | Bullish Swing Setup | -70.04% | |
| Volume Surge | Other | -70.04% | |
| NR7 | Range Contraction | -70.04% | |
| Narrow Range Bar | Range Contraction | -70.04% |
| Alert | Time |
|---|---|
| No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. | |
Get a Trading Sidekick!
- Earnings date: 05/10/2024
Biohaven Pharmaceutical Holding Company Ltd. Description
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Neuroscience Organic Compounds Chemical Compounds Neurodegenerative Diseases Glutamate Neurotransmitters Chemical Entity N Methyl D Aspartic Acid Riluzole
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 62.21 |
| 52 Week Low | 13.47 |
| Average Volume | 1,453,646 |
| 200-Day Moving Average | 35.88 |
| 50-Day Moving Average | 49.62 |
| 20-Day Moving Average | 41.87 |
| 10-Day Moving Average | 40.04 |
| Average True Range | 2.48 |
| RSI (14) | 39.39 |
| ADX | 21.29 |
| +DI | 19.90 |
| -DI | 25.69 |
| Chandelier Exit (Long, 3 ATRs) | 46.35 |
| Chandelier Exit (Short, 3 ATRs) | 44.22 |
| Upper Bollinger Bands | 50.31 |
| Lower Bollinger Band | 33.42 |
| Percent B (%b) | 0.44 |
| BandWidth | 40.33 |
| MACD Line | -2.57 |
| MACD Signal Line | -3.06 |
| MACD Histogram | 0.4922 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 42.91 | ||||
| Resistance 3 (R3) | 42.83 | 42.04 | 42.56 | ||
| Resistance 2 (R2) | 42.04 | 41.50 | 42.08 | 42.44 | |
| Resistance 1 (R1) | 41.41 | 41.16 | 41.02 | 41.49 | 42.32 |
| Pivot Point | 40.62 | 40.62 | 40.42 | 40.66 | 40.62 |
| Support 1 (S1) | 39.99 | 40.08 | 39.60 | 40.07 | 39.24 |
| Support 2 (S2) | 39.20 | 39.74 | 39.24 | 39.12 | |
| Support 3 (S3) | 38.57 | 39.20 | 39.01 | ||
| Support 4 (S4) | 38.65 |
